Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

Core Insights - Revive Therapeutics Ltd. is conducting a research study on Bucillamine as a potential treatment for nerve agent exposure in collaboration with Defence R&D Canada [1][2] - The study is ongoing, and final findings will be released with DRDC's authorization [2] - Revive is focused on developing therapeutics for infectious diseases and medical countermeasures, leveraging various FDA regulatory incentives [3] Company Overview - Revive Therapeutics specializes in the research and development of therapeutics for infectious diseases and medical countermeasures [3] - The company is exploring Bucillamine for nerve agent exposure and long COVID, alongside developing Psilocybin and molecular hydrogen therapeutics [3] Collaboration Details - The collaboration with DRDC provides expertise and infrastructure to support the development of medical countermeasures against nerve agent-induced brain injury [1]